This downturn is primarily attributed to a continued increase in medical costs for government-backed insurance plans, ...

Centene reported $42.5 billion in premium and service revenue for the quarter. However, adjusted EPS came in at a loss of ...

Analysts have given Centene a total of 16 ratings, with the consensus rating being Neutral. The average one-year price target is $49.62, indicating a potential 68.66% upside.

The story has been updated with executive comment and stock price change Healthcare insurance giant Centene Corporation (NYSE ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Centene’s stock has been in a free fall since early this month when the St. Louis-based payer pulled its earnings guidance for 2025 citing unexpectedly high spending on its ACA and Medicaid members.

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

Debt Management: Centene's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66. Understanding the Relevance of Analyst Ratings ...

J.P. Morgan analyst John Stansel downgraded Centene's stock to neutral from overweight, as it remains unclear how the company will be able to correct its healthcare pricing in 2026, given the ...

Centene's 40% drop offers a buying opportunity as valuation becomes attractive. Read why I think CNC stock is now attractively priced enough to consider a buy.